Peptide name : Elastin derived peptide

Source/Organism : Elastin derived

Linear/Cyclic : Not found

Chirality : Not found

Peptide length: 6

C-terminal modification: Not found

N-terminal modification : Free

Non-natural peptide information: None

Assay type : Cell viability assay

Assay time : 24h

Activity : Not found

Cell line : A549

Cancer type : Lung cancer

Other activity : Not found

Amino acid composition bar chart :

Molecular mass : 498.573 Dalton

Aliphatic index : 1.133

Instability index : 26.2833

Hydrophobicity (GRAVY) : 1.3

Isoelectric point : 5.495

Charge (pH 7) : -0.266

Aromaticity : 0

Molar extinction coefficient (cysteine, cystine): (0, 0)

Hydrophobic/hydrophilic ratio : infinite

hydrophobic moment : 0.0506

Missing amino acid : W,T,I,M,E,K,F,D,N,C,R,H,Q,S,Y,L

Most occurring amino acid : V

Most occurring amino acid frequency : 2

Least occurring amino acid : A

Least occurring amino acid frequency : 1

Secondary structure fraction (Helix, Turn, Sheet): (0.1, 0.5, 0.3)

SMILES Notation: CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C

1 : Szychowski KA, et al. Effect of the elastin-derived peptides (VGVAPG and VVGPGA) on breast (MCF-7) and lung (A549) cancer cell lines in vitro. Biomed Pharmacother. 2022; 151:113149. doi: 10.1016/j.biopha.2022.113149

Paper title : Effect of the elastin-derived peptides (VGVAPG and VVGPGA) on breast (MCF-7) and lung (A549) cancer cell lines in vitro.

Doi : https://doi.org/10.1016/j.biopha.2022.113149

Abstract : Tissues are subjected to dynamic communication between cells and the extracellular matrix (ECM), resulting in ECM remodeling. One of the ECM components is elastin, which releases elastin-derived peptides (EDPs) during the aging process. Therefore, the aim of the present study was to evaluate the impact of the VGVAPG hexapeptide and elastin-like peptide VVGPGA (control) on certain metabolism parameters in human breast adenocarcinoma (MCF-7) and human lung carcinoma (A549) cell lines. The results did not show a significant effect of the peptides on metabolic activity and caspase-3 activity. However, more specific analysis revealed that VGVAPG and VVGPGA were able to increase KI67 protein expression in both tested cell lines after 24-h treatment. Moreover, the same correlation was observed at the KI67 gene level. VGVAPG also increased the P53, ATM and SHH gene expression in the A549 cells up to 19.08%, 20.74%, and 28.77%, respectively. Interestingly, the VGVAPG peptide exerted an effect on the expression of antioxidant enzymes SOD2 and CAT in the A549 and MCF-7 cells, especially after the 24-h treatment. Lastly, both peptides influenced the CAV1 and CLTC1 expression. Our results show that the tested EDPs have an effect on both A549 and MCF-7 cells at the cellular level. This may be correlated with the multidrug-resistance (MDR) phenotype in these cancer cells, which is an emerging problem in the current anticancer treatment. However, more research is needed in this field.